Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cardiac Amyloidosis in Patients With Aortic Stenosis
Sponsor: Shanghai Zhongshan Hospital
Summary
This study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS), compare the clinical characteristics between patients with isolated AS and those with AS complicated by CA (CA-AS), and simultaneously explore the impact of transcatheter aortic valve replacement (TAVR) on serum transthyretin (TTR) levels in patients with AS complicated by transthyretin amyloidosis (ATTR-AS), as well as its influence on the treatment outcomes of patients with isolated AS and ATTR-AS.
Official title: A Study on the Prevalence and Clinical Characteristics of Cardiac Amyloidosis in Patients With Aortic Stenosis
Key Details
Gender
All
Age Range
65 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
143
Start Date
2026-01-31
Completion Date
2028-05-31
Last Updated
2026-01-20
Healthy Volunteers
No
Interventions
transcatheter aortic valve replacement (TAVR)
TAVR is a minimally invasive cardiac interventional procedure that delivers a compressed artificial aortic valve to the diseased aortic valve site via peripheral blood vessels (e.g., the femoral artery) or the apex of the heart through a catheter, releases and deploys the valve to replace the original diseased valve leaflets, thereby restoring normal valve function and treating severe aortic stenosis (AS).